Clinical trials · New York
Refractory Multiple Myeloma clinical trials in New York
We’re tracking 44 recruiting refractory multiple myeloma studies with a site in New York — including Early Phase 1, Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT06297226RecruitingPhase 2
CAR T cell therapy for multiple myeloma
This trial tests a new CAR T cell therapy (arlocabtagene autoleucel) that targets a protein called GPRC5D on myeloma cells. It is for people whose multiple myeloma has come back or is not responding after trying at least four different types of treatment.
New York, New YorkAges 18 years+ - NCT06433947RecruitingPhase 1
Testing an experimental drug OPN-6602 for advanced multiple myeloma
This trial tests an experimental oral drug called OPN-6602 for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The main goal is to see if the drug is safe and tolerable, and to find the best dose.
Rochester, New YorkAges 18 years+ - NCT06622005RecruitingPhase 1
Testing SX-682 with standard drugs for relapsed myeloma
This trial tests a new drug called SX-682 added to a standard three-drug combination (carfilzomib, daratumumab, dexamethasone) for people with multiple myeloma that has returned or stopped responding to earlier treatments. The goal is to see if adding SX-682 can help control the cancer better.
Buffalo, New YorkAges 18 years+ - NCT06627751RecruitingPhase 2
Mezigdomide, Carfilzomib, and Dexamethasone for Relapsed Myeloma
This clinical trial tests a combination of three drugs—mezigdomide, carfilzomib, and dexamethasone—for people with multiple myeloma that has come back or stopped responding to prior treatments, especially when the disease has spread outside the bone (extramedullary disease). It aims to see if this new cocktail can shrink tumors and control myeloma more effectively.
Buffalo, New YorkAges 18 years+ - NCT06896916RecruitingPhase 1
Study of etentamig and a CELMoD drug for relapsed multiple myeloma
This trial tests a new combination of two drugs—etentamig given through a vein and a CELMoD pill—for people whose multiple myeloma has come back or stopped responding to treatment. The goal is to see if this combination is safe and helps control the disease.
New York, New YorkAges 18 years+ - NCT07105059RecruitingPhase 1
Teclistamab and mezigdomide for multiple myeloma
This trial tests a combination of two drugs—teclistamab (an immunotherapy) and mezigdomide (a targeted pill)—for people with multiple myeloma that has come back or not responded to previous treatments. The goal is to see if this new combination can help when other options have stopped working.
Commack, New YorkAges 18 years+ - NCT07116616RecruitingPhase 1/Phase 2
mRNA vaccine for relapsed or refractory multiple myeloma
This trial tests an experimental mRNA therapy called mRNA-2808 for people with multiple myeloma that has returned or stopped responding to prior treatments. It aims to see if it can help control the disease.
New York, New YorkAges 18 years+ - NCT04973605RecruitingPhase 1/Phase 2
Sonrotoclax with steroid and other drugs for multiple myeloma
This early-phase study tests sonrotoclax (a cancer medicine) in people with multiple myeloma that has come back or not responded to prior treatment. It also studies different combinations with dexamethasone plus other standard medicines, aiming to shrink tumors and improve control of the disease.
New York, New YorkAges 18 years+ - NCT02343042RecruitingPhase 1/Phase 2
Selinexor with standard therapies for multiple myeloma
This trial tests a new drug called selinexor (KPT-330) combined with various standard treatments for patients whose multiple myeloma has come back or stopped responding to therapy. The goal is to see if adding selinexor helps control the cancer better than current options, and to find the safest dose for different drug pairings.
New York, New YorkAges 18 years+ - NCT07073547RecruitingPhase 1
Study of AZD0120 for multiple myeloma patients
This trial tests a new drug, AZD0120, in people with multiple myeloma. It aims to find the right dose and see how safe and effective it is. The study includes both newly diagnosed and early relapsed patients.
New York, New YorkAges 18 years+ - NCT06827860RecruitingPhase 2
Talquetamab shot for elderly with relapsed multiple myeloma
This study tests a new drug called talquetamab, given as a shot under the skin, for older adults with multiple myeloma that has come back or stopped responding to earlier treatments. The goal is to see if it can help control the cancer with fewer side effects.
New York, New YorkAges 70 years+ - NCT04634552RecruitingPhase 2
Talquetamab study for relapsed or refractory multiple myeloma
This trial studies talquetamab, a medicine given to treat multiple myeloma that has come back or did not respond to prior treatment. It may help shrink tumors and improve disease control, depending on how your myeloma measures and your health status.
New York, New YorkAges 18 years+ - NCT05137054RecruitingPhase 1
Linvoseltamab combo for hard-to-treat multiple myeloma
This trial tests a new drug called linvoseltamab combined with other cancer treatments for people with multiple myeloma that has stopped responding to standard therapies. It may be an option if you have already tried several treatments and are looking for a new approach.
New York, New YorkAges 18 years+ - NCT06892522RecruitingPhase 1/Phase 2
T cell therapies for multiple myeloma
This trial tests new antibody treatments for multiple myeloma, given alone or with other drugs. It aims to see if they can control the disease and what side effects might occur.
New York, New YorkAges 18 years+ - NCT04300998Recruiting
CAR-T therapy study for older adults
This study looks at how well CAR-T cell therapy works and how safely it can be given to older adults. It is for people whose cancer or related blood condition has come back or did not respond, and who are receiving a standard (commercial) CAR-T product.
New York, New YorkAges 60 years+ - NCT05332054Enrolling by invitation
Long-term follow-up after prior Caribou treatment
This study checks your health over time after you previously took a Caribou medicine (or got it through a special access program). It helps researchers learn what happens in the longer run after the treatment.
New York, New YorkAges 18 years+ - NCT03016806Recruiting
Umbilical cord blood transplant from unrelated donors
This trial studies transplanting healthy blood-forming cells from an umbilical cord blood donor who is not related to you. It may help people with certain blood cancers, immune disorders, or other serious diseases when a standard transplant plan is needed.
Rochester, New YorkAges 2 months–75 years - NCT04988555RecruitingPhase 1/Phase 2
Study of an investigational drug for high-risk acute leukemia
This Phase 1/2 study tests enzomenib (DSP-5336) in people with relapsed or hard-to-treat acute leukemia (and, in some places, certain other blood cancers). The goal is to see how the drug works and how safe it is, especially for leukemia cases with specific genetic changes (KMT2A/MLL or NPM1).
Buffalo, New YorkAges 12 years+ - NCT05093335RecruitingEarly Phase 1
PET scan test for CXCR4 in many relapsed cancers
This early study tests a new PET scan tracer (a radioactive imaging agent) that may light up a cell marker called CXCR4 in certain blood and solid tumor cancers. It may help doctors see where cancers are and how much CXCR4 they have, which could guide future treatments.
New York, New YorkAges 18 years+ - NCT05932680RecruitingPhase 2
Continue teclistamab for a limited time in responding patients
This Phase 2 trial looks at stopping or limiting teclistamab after you’ve already had a good ongoing response. It aims to see if people can safely continue to benefit while using the medicine for a shorter time.
New York, New YorkAges 18 years+
Refractory Multiple Myeloma trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting refractory multiple myeloma studies listed above.
- Memorial Sloan Kettering Cancer Center · 7 studies
- Weill Cornell Medicine · 5 studies
- Columbia University Irving Medical Center · 3 studies
- Icahn School of Medicine at Mount Sinai · 3 studies
- Mount Sinai Health System · 2 studies
- Mount Sinai Hospital · 2 studies
- Roswell Park Cancer Institute · 2 studies
- Roswell Park Comprehensive Cancer Center · 2 studies
What taking part in a refractory multiple myeloma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Refractory Multiple Myeloma trials in other states
Common questions
- Are there refractory multiple myeloma clinical trials in New York?
- Yes. We're currently tracking 44 recruiting refractory multiple myeloma studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a refractory multiple myeloma study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a refractory multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New refractory multiple myeloma studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.